Eureka strikes $6M for cancer antibodies

Drug developer Eureka Therapeutics brought in $6 million in second-round financing to continue development of antibodies used to treat cancer, VentureWire reports. Harbinger Venture Management led the round, with contributions coming from Acorn Campus Ventures and Desert Spring Life Science Capital.

The Emeryville, Calif.-based company also conducts outsourced antibody research services for other firms. It previously raised $1.6 million in a 2006 first round of funding.

Next Story: Social search startup Mechanical Zoo raises $2M more
Previous Story: Cancer drug developer ChemoCentryx cancels IPO